Biosimilar Sponsors May Be Going Overboard On Clinical Data, FDA Says
Executive Summary
Studying multiple indications 'not the right way to approach biosimilars,' agency says; Amgen conducted more studies than needed for its proposed Humira biosimilar to enhance patient and physician confidence.
You may also be interested in...
Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA
Sandoz announces 'complete response' letter for its pegfilgrastim 351(k) filing, suggesting it’s a tough molecule to crack at the agency.
Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA
Sandoz announces 'complete response' letter for its pegfilgrastim 351(k) filing, suggesting it’s a tough molecule to crack at the agency.
Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action
FDA considering public statement reflecting its view that biosimilars not deemed interchangeable will not be substituted at pharmacy, but the extent such a statement would limit payer-driven practice remains in question.